The History of Vaccines

The History of Vaccines - World Immunization Week

Developing vaccines started over 200 years ago when Dr. Edward Jenner created the first vaccine designed to immunize against smallpox. In 1980, the World Health Organization (WHO) determined that smallpox, a disease that killed over 35% of its victims, was eradicated worldwide.

In the US, diseases once considered prevalent health risks now have vaccine options available allowing for large majorities to be immunized. Some of those diseases are: polio, tetanus, flu, hepatitis A & B, rubella, Hib, measles, whooping cough, pneumococcal, rotavirus, mumps, chickenpox, and diphtheria.

In 2020, all the world had its eyes on vaccine development as COVID-19 swept across every continent. Communities shut down trying to slow the spread and still the virus infected millions. Since the development of the COVID-19 vaccine, over 550 million doses have resulted in more than 220 million fully-vaccinated Americans. The vaccine was, and continues to be, the biggest key in combatting the virus; keeping many from serious complications.

Many vaccines are still needed for protection against viruses like Respiratory Syncytial Virus (RSV), for example. RSV is an easily transmittable virus that effects the lungs and airways, with symptoms similar to the flu or COVID-19. RSV infection represents a potential medical emergency for infants and adults over 60.

Right now, there are no approved vaccine options. Research studies can lead to impressive medical milestones like developing the first RSV vaccine. Our participant volunteers play a vital role in making that happen. Right now, Accellacare is enrolling an RSV vaccine research study for healthy adults ages 60+.

Participants will receive study vaccine and study-related care at no cost. Financial compensation will also be provided for time and travel. See if you qualify by filling out the form below.

Learn about the research participation process here.


When you register your interest with Accellacare, our clinical research specialists will review your information at no cost and connect you with studies you may be eligible for. When we find a match, Accellacare may contact you for further pre-screening or we may share your information with a local site office for them to contact you directly. Your data will be processed as outlined in the Accellacare privacy policy


Data Protection

As the data controller for the Improvingtreatments.co.uk, Accellacare is committed to protecting the information that you provide. Where you give us your consent, we may use your information to: (a) identify appropriate clinical trials for you and to let you know about them; and/or (b) send you invitations to participate in future study opportunities. You can withdraw your consent at any time, but we may continue some limited processing where we have other legal grounds for doing so.

Please enter the security code: